Peptides and Perimenopause: Early Hormonal Changes

What Is Perimenopause?

Perimenopause is the transition period before menopause — the time when your body’s production of estrogen and progesterone begins to fluctuate and eventually decline. It can start as early as your mid-30s and typically lasts 4–10 years.

Symptoms include irregular periods, hot flashes, night sweats, mood swings, brain fog, sleep disruption, and changes in libido. These aren’t just “hormonal” — they reflect real shifts in neuroendocrine signaling that affect the whole body.

The Hormonal Axis During Perimenopause

The hypothalamic-pituitary-gonadal (HPG) axis governs reproductive hormone production. During perimenopause, declining ovarian reserves mean the ovaries produce less estrogen. The pituitary responds by releasing more FSH (follicle-stimulating hormone) in an attempt to stimulate the ovaries — which is why elevated FSH is a marker of perimenopause.

The problem isn’t just estrogen — it’s the whole signaling cascade. Disrupted communication between the hypothalamus, pituitary, and ovaries contributes to the erratic symptoms women experience.

Kisspeptin-10 and Hormonal Signaling

Kisspeptin is a neuropeptide produced in the hypothalamus that acts as a master regulator of the HPG axis. It stimulates GnRH (gonadotropin-releasing hormone) release, which in turn drives LH and FSH secretion from the pituitary.

Research has investigated Kisspeptin-10 — the active fragment — as a tool to probe and potentially restore HPG axis signaling:

• A 2012 study in Journal of Clinical Investigation showed kisspeptin infusion significantly increased LH pulse frequency in perimenopausal women
• Kisspeptin neurons are themselves estrogen-sensitive, meaning declining estrogen in perimenopause can dysregulate kisspeptin signaling, worsening hormonal instability
• Research suggests kisspeptin may play a role in regulating hot flash frequency through its effects on thermoregulatory neurons

View Kisspeptin-10 →

PT-141 (Bremelanotide) and Libido Changes

Reduced libido is one of the most common complaints during perimenopause, and it’s often tied to shifts in central nervous system arousal rather than just estrogen levels.

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that acts centrally — in the brain — rather than through vascular mechanisms. It was originally developed from Melanotan II and has been FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

• Clinical trials showed PT-141 significantly improved sexual desire scores versus placebo in women with HSDD
• The mechanism — MC3R/MC4R agonism in the CNS — is distinct from estrogen pathways, making it relevant even in low-estrogen states
• Research is ongoing for its use in perimenopausal and postmenopausal populations

View PT-141 →

Gonadorelin and HPG Axis Research

Gonadorelin is the synthetic version of GnRH — the hormone that starts the hormonal cascade leading to estrogen and progesterone production. In research settings, pulsatile GnRH administration has been used to study and restore HPG axis function in women with hypothalamic dysfunction.

During perimenopause, GnRH pulsatility itself becomes disrupted. Research using gonadorelin aims to understand whether restoring pulsatile GnRH signaling can improve hormonal stability during this transition.

Important Limitations

Most peptide research in the context of perimenopause involves early-phase studies, small sample sizes, or mechanistic work in animals. None of the peptides discussed here have been approved to treat perimenopause symptoms. Women experiencing perimenopausal symptoms should consult a qualified healthcare provider about evidence-based options including hormone therapy.

Written by the NorthPeptide Research Team

Key Research References